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Abstract   
Introduction: Cervical cancer is the third most common tumor among women. Surgery, 
radiotherapy, and chemotherapy are common treatments, however high stage tumors have 
frequently poor prognosis. Nowadays, the epigenetic reversion introduced as an efficient 
strategy of treatment of cervical cancer. In the process, inhibitors of DNA methyltransferase 
(DNMT) induce re-expression of tumor suppressor genes. Among these inhibitors, disulfiram 
(DSF) has been suggested as non-nucleoside analogous. In this research, we evaluated the 
epigenetic effect of DSF on demethylation of the tumor suppressor gene, RASSF1A, in Hela 
cell line. 
Materials and methods: Hela cells were cultured and treated with different doses from 2.5 to 
37.5µM during 24, 48 and 72 hours. MTT assay was carried out to find half maximal inhibitory 
concentration (IC50). The methylation specific PCR (MSP) assay was applied to evaluate 
methylation pattern. 
Results: The IC50 of DSF was determined at the 2.5, 12.5, and 15µM after72 hours. The MSP 
results showed partial demethylation at mentioned concentrations after 72h but unmethylated 
band was not observed after 24h. 
Conclusion: Our findings indicated that, IC50 of DSF exerted a biphasic effect in Hela cell line 
and at least 72 hours treatment is needed for the epigenetic reversion of DSF on RASSF1Ain 
Hela cell line. 
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Introduction  
Cervical cancer is the third most common 
cancer among women; around 70% of the 
patients are infected by HPV (16/18) 
virus(1-2). Unfortunately, this neoplasia is 
one of the most common life-threatening 
diseases in the world and the patients 
usually have less than 5 years survival time 
after diagnosis. Although combined 
treatment of chemotherapy, surgery and 
radiotherapy are recommended for this 
cancer, still it has poor prognosis(3-4). 
Recent studies have demonstrated the role 
of epigenetic and genetic factors in 
tumorogenesis. Epigenetic events show 
phenotype alterations without genetic 
alterations(5). DNA hypermethylation and 
histone modification are two important 
epigenetic events (6). DNA 
hypermethylation in CPG Islands of 
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promoter region in tumor suppressor genes 
induces gene silencing without alteration in 
DNA sequences which are inherited from 
one generation to the next (7-8). 
RASSF1A is one of the critical tumor 
suppressor genes that induce apoptotic 
signaling, microtubule stability and cell 
cycle arrest (9). In one hand, the 
inactivation of tumor suppressor genes 
usually occurs by mutation in one allele and 
hypermethylation in the others. RASSF1A 
inactivation was reported in different kind 
of cancers such as lung, breast, bladder, 
prostate, kidney and cervix (10). On the 
other hand, RASSF1A is routinely 
expressed in normal tissue and regulates 
normal cell cycle, apoptosis, DNA repair 
and inhibits tumorigenesis (9). Fortunately, 
the epigenetic events are reversible, for 
instance using DNA methyl-transferase 
inhibitor (DNMTi) drugs are recommended 
to revise abnormal methylation in promoter 
region of tumor suppressor genes(11). The 
DNMTs inhibitor drugs are characterized in 
two groups, which called the cytosine 
analogous and non-cytosine analogous(12). 
The cytosine analogous DNMTi such as 5-
Aza-CdR which was approved by FDA and 
used as combined cancer therapy in 
lymphoma and hematopoietic cancer is 
toxic(13). As a result, cytosine-like 
structure in this group can replace cytosine 
during DNA duplication that induces 
mutation. Thus,taking steps to find a new 
approach of cancer therapy of non-
nucleoside analogous of DNMT inhibitors 
seems to be obligatory(14). 
For more than 50 years, DSF has been 
advised for alcohol abuse, but, recent 
studies have demonstrated the anti-
neoplastic effect of this drug on different 
tumors and cancer cell lines such as 
Melanoma, glioma, lung carcinoma, and 
leukemia(15). Because of strong reactive 
functional thiol groups in chemical 
structure of DSF, DSF is suggested as a 
non-nucleoside analogous of DNMT 
inhibitors that can be able to attack the 
cytosine sites on DNA to remove 
methylated group (16). The exact anti-
neoplastic effect of DSF is not clear, so in 
this study we investigated the epigenetic 
effect of DSF on re-expression of 
RASFF1A on cervical cancer cell line.    
Material and methods 
Cell line and cell culture: Hela was 
prepared from the cellular and molecular 
lab of Babol University of Medical 
Sciences, and MRC-5 was obtained from 
National Cell Bank of Pasteur Institute of 
Iran. Cells were cultured in RPMI 
(Biowest, France), 10% FBS, 1% penicillin 
streptomycin (Sigma, USA) at 37˚C and 5% 
CO2. When they reach 80% confluence, 
2×104 cells were transferred to 24 well cell 
cultures.  
DSF treatment: The stock solution of DSF 
(50mM) was dissolved in DMSO (Sigma, 
USA) and stored at 20˚C. Serial dilutions 
were prepared in different concentrations 
based on drug reference. Cells were treated 
with 0, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 
22.5, 25, 27.5, 30, 32.5, 35 µM one day 
after seeding for24, 48 and 72h. The IC50 of 
DSF was obtained at 2.5, 12.5, 15 µM for 
72h. 
MTT assay: The cytotoxicity of DSF was 
determined in Hela cell line using MTT 
assay. 2×104 cells were cultured in each 
well of a 24 well plate overnight, after that 
and treatment, the MTT assay was pre-
formed as described previously (17). 
DNA extraction, bisulfate treatment, and 
methylation specific PCR: Genomic 
DNAs were extracted from treated and 
control groups of Hela and MRC-5 cells (as 
unmethylated control) using Prime Prep 
TM Genomic DNA Isolation Kit (Genet 
bio, Korea) according to manufacturer's 
instructions. The amount of DNA 
extraction was measured by nano drop. The 
bisulfate modification of genomic DNA 
was performed on 2-µl of genomic DNA 
using Epitect Bisulfite kit (Qiagen, 
Germany) according to the protocol. The 
PCR reaction was performed in thermal 
cycler (Thermocycler, Germany) for 
methylated primers as: 95˚C for 5min 
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for 30s, and 72˚C for 30s and final 
extension 72˚C for 4min.  
For unmethylated primers the cycling 
program was as: 95˚C for 5 min followed 
by 35 cycles of 94˚C for 30s, 55.3˚C for 
30s, 72˚C for 30s, the final extension 72˚C 
for 4min. The PCR products were 
transferred to electrophoresis on 2% 
agarose gel and visualized with ethidium 
bromide (17). 
Result 
The IC50 of DSF was determined 2.5, 12.5, 
15 µM for 72h by MTT assay and 50%, 
45% and 43% of Hela cells were alive at 
mentioned concentrations, respectively. 
The IC50 and the percentage of apoptotic 
cells were not remarkable after 24 and 48h 
of treatment. The results demonstrated a 
biphasic effect of DSF doses on Hela cells 
(Figure 1).  
Methylation specific PCR (MSP) result: 
The methylation specific PCR has not 
demonstrated any unmethylated band after 
being treated with 2.5, 12.5, 15 µM after 
24h treatment (Figure 2). Partial 
demethylation was observed after treatment 
in the mentioned concentrations. After 72h, 
both methylated and unmethylated bands 




Figure 1. Cell viability percentage of Hela cells after treatment with 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 





Figure 2. MSP assay was carried out to determine promoter RASSF1A methylation and unmethylation in Hela 
cancer cell line after DSF treatment for 24h. There was not observed any unmethylated band after treatment.  

























































Figure 5. MSP assay was carried out to determine promoter RASSF1A methylation and unmethylation in Hela 
cancer cell line after DSF treatment for 72h. Both unmethylated and methylated bands were obtained after 
treatment with 2.5, 12.5 and 15µM concentrations. 
(C: control, 2.5, 12.5, 15µM DSF treatment, F: fibroblast) 
Discussion 
DNA methylation is one of the significant 
epigenetic events in tumorogenesis(16). 
The important reason of alteration in DNA 
methylation pattern is the increase of 
DNMT enzyme activity in malignant 
tumors (5). The methylation of CpGs island 
promoter region of RASSF1A tumor 
suppressor genes are reported in different 
type of cancers and cancer cell lines (18). 
Recent studies have demonstrated DNMTs 
inhibitors as a new strategy in cancer 
therapy as combined treatment (19). 
In this study, we evaluated the apoptotic 
effect of DSF in Hela cancer cell line. The 
result showed no apoptotic effect of DSF in 
Hela cell line after 24h of treatment. 
Moreover, the 48h treatment of DSF in 
Hela cell line declared no significant 
decrease of cell viability as well. 
Nevertheless, the IC50 of DSF was obtained 
after 72h treatment. The IC50 indicated 
biphasic effect at 2.5, 5, 12.5 µM 
concentrations in Hela cell line. 
Our results were in accordance with the 
studies of Wiggins, Zhang, and Jones that 
demonstrated the biphasic effect of DSF 
inMCF-7, HePG2, and ovarian cancer cell 
line(OVCAR-3) (20-22), while 
Wickstorms and Nikbakht stated the 
monophasic effect of DSF in ACH, 
H69AR, PRE and PANC-1, 
respectively(17, 23). This controversy can 
be explained by different responses of 
various cancer cell lines and tumor cells 
during the exposure of DSF. Furthermore, 
we investigated the epigenetic effect of 
DSF on demethylation of RASSF1Ain Hela 
cancer cell line. The result exhibited no 
epigenetic effect and no demethylation of 
promoter RASSF1A after 24h treatment 
while partial demethylation was observed 
through 72h treatment. Our results are 
similar with the study of Sherma that 
explained DSF as DNMTs inhibitors, 
induced demethylation and re-expressed 
ER-B in prostate cancer cell line (24). On 
the other hand, our results are in contrast 
with Nikbakht that demonstrated no 
epigenetic effect but apoptotic effect of 
DSF on PANC-1(17). This controversy can 
be explained as time dependent epigenetic 
reversion of disulfiram, to be exact 24h is 
not a sufficient time for epigenetic 
reversion. Stresemann stated at least 72h 
treatment is essential for epigenetic 
reversion which was in accordance with our 
results (25). However, Christoforou 
explained the decrease of DNMT enzyme 
activity on DU145 and prostate cancer cell 
line(PC-3)after 48h treatment with 
DSF(26). This controversy can be related to 
different doses, time dependent and 
different response mechanisms of tumor 







































DSF showed partial demethylation after 
72h treatment while no epigenetic reversion 
was found after 24h. In conclusion, we can 
found that DSF has time dependent 
epigenetic effect on CpG island promoter 
region of RASSF1A. As DSF is asafe drug 
and induces tumor specific toxicity, it is 
worth using it as acombined cancer therapy 
drug with chemotherapy and radiotherapy. 
In summary, our results showed the time 
dependent epigenetic effect of DSF in Hela 
cell line. After 72h treatment, partial 
demethylation occurred in 2.5, 12.5 and 15 
µM concentrations. 
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